BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $62,218 | -89.0% | 310,777 | +12.7% | 0.00% | – |
Q2 2023 | $567,954 | -37.6% | 275,706 | 0.0% | 0.00% | – |
Q1 2023 | $909,829 | +202986.8% | 275,706 | +0.7% | 0.00% | – |
Q4 2022 | $448 | -100.0% | 273,706 | -1.1% | 0.00% | – |
Q3 2022 | $1,222,000 | +60.6% | 276,636 | +0.3% | 0.00% | – |
Q2 2022 | $761,000 | -20.1% | 275,909 | -2.7% | 0.00% | – |
Q1 2022 | $952,000 | -14.4% | 283,485 | +1.9% | 0.00% | – |
Q4 2021 | $1,112,000 | +22.3% | 278,101 | +0.9% | 0.00% | – |
Q3 2021 | $909,000 | -9.7% | 275,750 | +4.0% | 0.00% | – |
Q2 2021 | $1,007,000 | -45.0% | 265,138 | -44.6% | 0.00% | – |
Q1 2021 | $1,831,000 | -0.3% | 478,258 | +17.8% | 0.00% | – |
Q4 2020 | $1,836,000 | -72.9% | 405,923 | +1.5% | 0.00% | -100.0% |
Q3 2020 | $6,766,000 | +53.4% | 399,906 | +1.6% | 0.00% | 0.0% |
Q2 2020 | $4,411,000 | +461.2% | 393,522 | +132.1% | 0.00% | – |
Q1 2020 | $786,000 | -35.9% | 169,585 | -40.8% | 0.00% | – |
Q4 2019 | $1,226,000 | +119.7% | 286,472 | +100.0% | 0.00% | – |
Q3 2019 | $558,000 | +7.1% | 143,236 | +8.5% | 0.00% | – |
Q2 2019 | $521,000 | +14.3% | 132,063 | +25.4% | 0.00% | – |
Q1 2019 | $456,000 | -38.9% | 105,273 | -50.0% | 0.00% | – |
Q4 2018 | $746,000 | +85.6% | 210,546 | +100.0% | 0.00% | – |
Q3 2018 | $402,000 | -2.0% | 105,273 | 0.0% | 0.00% | – |
Q2 2018 | $410,000 | +52.4% | 105,273 | +22.8% | 0.00% | – |
Q1 2018 | $269,000 | -19.7% | 85,710 | 0.0% | 0.00% | – |
Q4 2017 | $335,000 | -5.1% | 85,710 | 0.0% | 0.00% | – |
Q3 2017 | $353,000 | -0.8% | 85,710 | 0.0% | 0.00% | – |
Q2 2017 | $356,000 | +14.5% | 85,710 | +16.8% | 0.00% | – |
Q1 2017 | $311,000 | +100.6% | 73,366 | +19.7% | 0.00% | – |
Q4 2016 | $155,000 | +6.2% | 61,269 | 0.0% | 0.00% | – |
Q3 2016 | $146,000 | -0.7% | 61,269 | 0.0% | 0.00% | – |
Q2 2016 | $147,000 | -9.8% | 61,269 | 0.0% | 0.00% | – |
Q1 2016 | $163,000 | -6.9% | 61,269 | 0.0% | 0.00% | – |
Q4 2015 | $175,000 | +25.0% | 61,269 | 0.0% | 0.00% | – |
Q3 2015 | $140,000 | -36.7% | 61,269 | 0.0% | 0.00% | – |
Q2 2015 | $221,000 | -18.8% | 61,269 | 0.0% | 0.00% | – |
Q1 2015 | $272,000 | +231.7% | 61,269 | +255.5% | 0.00% | – |
Q4 2014 | $82,000 | – | 17,235 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Weaver Consulting Group | 130,000 | $437,000 | 0.21% |
Ikarian Capital, LLC | 304,161 | $1,022,000 | 0.13% |
ABNER HERRMAN & BROCK LLC | 265,000 | $890,000 | 0.12% |
S.C. Financial Services, Inc. | 15,285 | $51,000 | 0.06% |
JMAC ENTERPRISES LLC | 45,430 | $153,000 | 0.04% |
CFO4Life Group, LLC | 12,000 | $40,000 | 0.01% |
OSAIC HOLDINGS, INC. | 10,839 | $1,329,000 | 0.00% |
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 3,000 | $10,000 | 0.00% |
BOOTHBAY FUND MANAGEMENT, LLC | 29,186 | $98,000 | 0.00% |
RAYMOND JAMES & ASSOCIATES | 190,403 | $640,000 | 0.00% |